Cd4 t cells clone gk1.5

All animals were housed in a barrier facility in air-filtered cages. As indicated for selected experiments 1 × 10⁶ Lewis Lung Carcinoma cells (ATCC®) in the logarithmic phase of growth were injected subcutaneously into the flank. For specific experiments, mice were depleted of NK cells (clone PK136), CD8⁺ (clone YTS169.4) and/or CD4⁺ T cells (clone GK1.5)(BioXcell). C57BL/6 mice expressing cherry tomato-red on an NK1.1 promoter was previously described.⁵⁶ (link) All animal procedures were approved by the Animal Studies Committee at Washington University School of Medicine, St. Louis, Missouri, USA and University of Tübingen and carried out according to the guidelines of the German Law for the Protection of Animals.

A total of 5 × 10⁵ AKR cells were resuspended in 100 μl PBS and s.c. inoculated in the flanks of 6‐wk‐old female C57BL/6 mice (H‐2b) and nude athymic mice (strain NU/NU Crl:NUFoxn1nu), respectively. DEX_A‐P, DEX_VEC and PBS were administered i.v. into 7‐day‐established AKR tumour‐bearing mice every 5 days for three times, respectively. Tumour volumes were measured every 5 days, and tumour mass was calculated using the following formula: volume = 0.5236 × length × width². Mice were sacrificed by cervical dislocation at desired time‐points, and tumours were excised for paraffin block preservation. For T‐cell depletion studies, antibodies to deplete CD4⁺ T cells (clone GK1.5; BioXcell) or CD8⁺ T cells (clone 2.43; BioXcell) were injected i.p. at 100 μg per mouse on day 5, 10, 15 and every other 5 days thereafter until completion of the study. 7‐day‐established AKR tumour‐bearing mice were treated three times with DEX_A‐P (40 μg) i.v. and were monitored for tumour growth, body weight and survival. The extent of T cell depletion was determined at the end of the study by flow cytometry of PBL and spleen cell homogenate. Animal experiments were reviewed and approved by the Ethics Committee of Shantou University Medical College.